Watchlist Price Alert

Novavax Inc. (NVAX)

NASDAQ: NVAX · Real-Time Price · USD

6.18

-0.01 (-0.16%)

At close: May 13, 2025, 3:59 PM

-0.16% (1D)

Bid	6.18
Market Cap	1B
Revenue (ttm)	1.25B
Net Income (ttm)	478.7M
EPS (ttm)	2.75
PE Ratio (ttm)	2.25
Forward PE	11.53
Analyst	Buy

Ask	6.19
Volume	381,033
Avg. Volume (20D)	6,480,518
Open	6.20
Previous Close	6.19
Day's Range	6.14 - 6.28
52-Week Range	5.01 - 23.86
Beta	3.21

About NVAX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NVAX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Novavax has released their quartely earnings on May 8, 2025:

Revenue of $666.65M exceeds estimates by $594.88M, with 610.30% YoY growth.

EPS of 2.93 exceeds estimates by 2.74, with 379.05% YoY growth.

Why Price Moved

5 days ago

+11.93%

Novavax shares are trading higher after the compan... Unlock content with Pro Subscription

1 week ago

-3.19%

Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.

News

15 hours ago · zacks.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

2 days ago · seekingalpha.com

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven ...

4 days ago · zacks.com

Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

4 days ago · zacks.com

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.

6 days ago · benzinga.com

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.

6 days ago · seekingalpha.com

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

Novavax, Inc. (NASDAQ:NVAX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Of...

6 days ago · barrons.com

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%

Novavax has seen its shares plummet since the pandemic because of weakening demand.

5 days ago · zacks.com

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago.

5 days ago · reuters.com

Novavax swings to profit on lower expenses related to COVID shots

Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.

1 week ago · youtube.com

New vaccine chief rocks pharmaceutical stocks

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

Load More News